{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'Safety and rights of subjects are being protected.', 'Study is conducted in accordance with the currently approved protocol and any other', 'study agreements, GCP, and all applicable regulatory requirements.', 'The extent and nature of monitoring will be described in a written monitoring plan on file at', 'GSK CH. The investigator (or designee) agrees to allow the monitor direct access to all relevant', 'documents and agrees to co-operate with the monitor to ensure that any problems detected in', 'the course of these monitoring visits are resolved.', '13.2', 'Quality Assurance', 'To ensure compliance with GCP and all applicable regulatory requirements, GSK CH may', 'conduct a quality assurance assessment and/or audit of the site records, and the regulatory', 'agencies may conduct a regulatory inspection at any time during or after completion of the study.', 'In the event of an assessment, audit or inspection, the investigator (and institution) must agree', 'to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and', 'to allocate their time and the time of their staff to discuss the conduct of the study, any', 'findings/relevant issues and to implement any corrective and/or preventative actions to address', 'any findings/issues identified.', 'The investigator(s) will notify GSK CH or its agents immediately of any regulatory inspection', 'notification in relation to the study. Furthermore, the investigator will cooperate with GSK CH', 'or its agents to prepare the study site for the inspection and will allow GSK CH or its agent,', 'whenever feasible, to be present during the inspection. The investigator will promptly apply', 'copies of the inspection finding to GSK CH or its agent. Before response submission to the', 'regulatory authority, the investigator will provide GSK CH or its agents with an opportunity to', 'review and comment on responses to any such findings.', 'The Sponsor will be available to help investigators prepare for an inspection.', '13.3', 'Regulatory and Ethical Considerations', '13.3.1', 'Institutional Review Board/ Ethics Committee', 'It is the responsibility of the investigator to have prospective approval of the study protocol,', 'protocol amendments, informed consent documents, investigator brochure/safety statement', '(including any updates) and other relevant documents, e.g. recruitment advertisements, if', 'applicable, from the IRB/EC. All correspondence with the IRB/EC should be retained in the', 'investigator file. Copies of IRB/EC approvals should be forwarded to GSK CH prior to the', 'initiation of the study, and also when subsequent amendments to the protocol are made.', 'The only circumstance in which an amendment may be initiated prior to IRB/EC approval is', 'where the change is necessary to eliminate apparent immediate hazards to the subjects. In that', 'event, the investigator must notify the IRB/EC and GSK CH in writing immediately after the', 'implementation.', '13.3.2 Ethical Conduct of the Study', 'The study will be conducted in accordance with legal and regulatory requirements, as well as', 'the general principles set forth in the International Ethical Guidelines for Biomedical Research', 'Involving Human Subjects (Council for International Organizations of Medical Sciences 2002),', 'International Ethical Guidelines for Health-Related Research Involving Humans (Council for', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 52 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'International Organizations of Medical Sciences, 2016), guidelines for GCP (ICH 1996 and', 'revision 2), and the Declaration of Helsinki (World Medical Association, 2013).', 'In addition, the study will be conducted in accordance with the protocol, the ICH guideline on', 'GCP (ICH, Nov 2016) , and applicable local regulatory requirements and laws.', '13.3.3', 'Subject Information and Consent', 'All parties will ensure protection of subject personal data and will not include subject names or', 'other identifiable data in any reports, publications, or other disclosures, except where required', 'by laws.', 'When study data are compiled for transfer to GSK CH and other authorized parties, subject', 'names, addresses, and other identifiable data will be replaced by numerical codes based on a', 'numbering system provided by GSK CH in order to de-identify study subjects.', 'The study site will maintain a confidential list of subjects who participated in the study, linking', \"each subject's numerical code to his or her actual identity. In case of data transfer, GSK CH\", \"will maintain high standards of confidentiality and protection of subjects' personal data\", 'consistent with applicable privacy laws.', 'The informed consent documents must be in compliance with ICH GCP, local regulatory', 'requirements, and legal requirements, including applicable privacy laws.', 'The informed consent documents used during the informed consent process must be reviewed', 'and approved by the Sponsor, approved by the IRB/EC before use, and available for inspection.', 'The investigator must ensure that each study subject, is fully informed about the nature and', 'objectives of the study and possible risks associated with participation.', 'The investigator, or a person designated by the investigator, will obtain written informed', 'consent from each subject before any study-specific activity is performed. The investigator will', \"retain the original of each subject's signed informed consent document.\", '13.3.4', 'Subject Recruitment', 'Advertisements approved by IRBs/ECs and investigator databases may be used as recruitment', 'procedures. Use of ethics committee approved, generic, prescreening questionnaire to assess', 'basic subject characteristics to determine general eligibility for this study is allowed. This', 'generic questionnaire may be used by sites as a phone script and/or to review internal databases', 'to identify subjects.', 'GSK CH will have an opportunity to review and approve the content of any study recruitment', 'materials directed to potential study subjects before such materials are used.', '13.3.5', 'Reporting of Safety Issues and Serious Breaches of the Protocol or', 'ICH GCP', 'Within GSK CH a serious breach is defined as a breach likely to affect to a significant degree', 'the safety and rights of a subject or the reliability and robustness of the data generated in GSK', 'CH-Sponsored human subject research studies.', 'In the event of any prohibition or restriction imposed (i.e., clinical hold) by an applicable', 'competent authority in any area of the world, or if the investigator is aware of any new', 'information that might influence the evaluation of the benefits and risks of the investigational', 'product, GSK CH should be informed immediately.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 53 of 65']\n\n###\n\n", "completion": "END"}